Aspera Biomedicines Advances Cancer Research with SpaceX ISS Mission
Aspera Biomedicines has successfully launched its second ADAR1p150 protein crystallization experiment to the International Space Station (ISS) aboard SpaceX CRS-34. This mission aims to advance the development of an oral formulation of Rebecsinib, a therapeutic targeting cancer stem cells. The experiment utilizes Redwire Corporation's Pharmaceutical In-space Laboratory (PIL-BOX) technology to crystallize proteins in microgravity, providing structural insights that are unattainable on Earth. These insights are crucial for improving drug formulations and broadening patient access. The mission builds on Aspera's previous experiment and is funded by NASA's In Space Production Applications (InSPA) Phase 2 award. 
